Announcement • Jun 20
Genetic Signatures Limited Announces Executive Changes, Effective June 19, 2026 Genetic Signatures Limited announced that Sonya Tissera had been appointed as Company Secretary effective June 19, 2026. For the purposes of ASX Listing Rule 12.6, Sonya Tissera is also the person responsible for communication between the Company and ASX. Michael Sapountzis stepped down from his role as Company Secretary with effect from June 19, 2026. Reported Earnings • Mar 03
First half 2026 earnings released: AU$0.028 loss per share (vs AU$0.069 loss in 1H 2025) First half 2026 results: AU$0.028 loss per share (improved from AU$0.069 loss in 1H 2025). Revenue: AU$8.68m (up 2.1% from 1H 2025). Net loss: AU$6.37m (loss narrowed 58% from 1H 2025). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Global Life Sciences industry. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings. Announcement • Feb 18
Genetic Signatures Limited to Report First Half, 2026 Results on Feb 26, 2026 Genetic Signatures Limited announced that they will report first half, 2026 results on Feb 26, 2026 New Risk • Jan 24
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: AU$20m Forecast net loss in 3 years: AU$3.5m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$3.5m net loss in 3 years). Market cap is less than US$100m (AU$40.9m market cap, or US$28.2m). Breakeven Date Change • Jan 23
Forecast to breakeven in 2028 The 2 analysts covering Genetic Signatures expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 30% per year to 2027. The company is expected to make a profit of AU$3.30m in 2028. Average annual earnings growth of 62% is required to achieve expected profit on schedule. Announcement • Oct 16
Genetic Signatures Limited, Annual General Meeting, Nov 17, 2025 Genetic Signatures Limited, Annual General Meeting, Nov 17, 2025. Location: allens, deutsche bank place, level 28, 126 phillip street, sydney nsw 2000, Australia Major Estimate Revision • Sep 09
Consensus EPS estimates upgraded to AU$0.065 loss The consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -AU$0.073 to -AU$0.065 per share. Revenue forecast steady at AU$20.7m. Life Sciences industry in Australia expected to see average net income growth of 17% next year. Consensus price target down from AU$0.64 to AU$0.57. Share price fell 10% to AU$0.26 over the past week. New Risk • Sep 08
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: AU$20m Forecast net loss in 3 years: AU$1.2m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (AU$1.2m net loss in 3 years). Market cap is less than US$100m (AU$63.6m market cap, or US$41.7m). Breakeven Date Change • Aug 27
Forecast to breakeven in 2028 The 2 analysts covering Genetic Signatures expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 28% per year to 2027. The company is expected to make a profit of AU$3.30m in 2028. Average annual earnings growth of 55% is required to achieve expected profit on schedule. Reported Earnings • Aug 27
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: AU$0.089 loss per share. Revenue: AU$19.8m (up 44% from FY 2024). Net loss: AU$20.1m (loss widened 13% from FY 2024). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 8.5% growth forecast for the Global Life Sciences industry. Announcement • Aug 20
Genetic Signatures Limited to Report Fiscal Year 2025 Results on Aug 25, 2025 Genetic Signatures Limited announced that they will report fiscal year 2025 results on Aug 25, 2025 Announcement • Aug 18
Genetic Signatures Limited Announces Appointment of Dr Susanne Pedersen as Chief Technology Officer Genetic Signatures Limited appointed Dr Susanne Pedersen to the role of Chief Technology Officer (CTO). Dr Pedersen has a PhD in molecular biology and over 25 years of experience in the development and commercialisation of molecular in vitro diagnostic (IVD) products. Dr Pedersen was a co-founder of Clinical Genomics Pty Ltd. where, as Vice President of Science & Innovation, she led the discovery, development and commercialisation of ColveraTM - Australia' first CLIA-accredited liquid biopsy for colorectal cancer. Through this role, Dr Pedersen established in-depth technical expertise in the discovery and validation of clinically relevant biomarkers (DNA, RNA and proteins) as well as extensive experience in the regulatory, clinical and quality requirements for developing commercial molecular IVD products. Dr Pedersen will have primary responsibility for managing the development of Genetic Signatures' technology and molecular diagnostic products. This will include ongoing initiatives to optimise and streamline Genetic Signature's 3base® technology platform and workflow, the development of new molecular syndromic IVD tests and test products, and overseeing the development of automated, high-throughput systems through the customisation of commercially available instruments. Price Target Changed • Jul 29
Price target decreased by 22% to AU$0.69 Down from AU$0.88, the current price target is an average from 2 analysts. New target price is 108% above last closing price of AU$0.33. Stock is down 57% over the past year. The company is forecast to post a net loss per share of AU$0.11 next year compared to a net loss per share of AU$0.11 last year. Price Target Changed • May 03
Price target decreased by 20% to AU$0.88 Down from AU$1.10, the current price target is an average from 2 analysts. New target price is 80% above last closing price of AU$0.48. Stock is down 31% over the past year. The company is forecast to post a net loss per share of AU$0.11 next year compared to a net loss per share of AU$0.11 last year. New Risk • May 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$11m net loss in 2 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (AU$110.2m market cap, or US$70.8m). New Risk • Apr 30
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: AU$23m Forecast net loss in 2 years: AU$11m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$11m net loss in 2 years). Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (AU$92.0m market cap, or US$58.8m). Announcement • Feb 25
Genetic Signatures Limited to Report First Half, 2025 Results on Feb 26, 2025 Genetic Signatures Limited announced that they will report first half, 2025 results on Feb 26, 2025 Major Estimate Revision • Feb 01
Consensus revenue estimates fall by 21% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from AU$24.3m to AU$19.1m. Forecast losses increased from -AU$0.048 to -AU$0.066 per share. Life Sciences industry in Australia expected to see average net income growth of 27% next year. Consensus price target down from AU$1.10 to AU$1.05. Share price was steady at AU$0.62 over the past week. New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 38% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Minor Risk Market cap is less than US$100m (AU$140.8m market cap, or US$87.7m). Announcement • Oct 18
Genetic Signatures Limited, Annual General Meeting, Nov 20, 2024 Genetic Signatures Limited, Annual General Meeting, Nov 20, 2024. Location: allens, deutsche bank place, level 28, 126 phillip street, sydney, nsw 2000 Australia New Risk • Oct 02
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: AU$139.5m (US$96.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Minor Risk Market cap is less than US$100m (AU$139.5m market cap, or US$96.3m). Major Estimate Revision • Sep 06
Consensus EPS estimates fall by 60% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -AU$0.03 to -AU$0.048 per share. Revenue forecast of AU$24.3m unchanged since last update. Life Sciences industry in Australia expected to see average net income growth of 29% next year. Consensus price target of AU$1.10 unchanged from last update. Share price fell 6.7% to AU$0.70 over the past week. Reported Earnings • Aug 31
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: AU$0.11 loss per share (further deteriorated from AU$0.098 loss in FY 2023). Revenue: AU$14.3m (down 33% from FY 2023). Net loss: AU$17.9m (loss widened 27% from FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 39%. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Global Life Sciences industry. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance. Announcement • Aug 22
Genetic Signatures Limited Announces Changes to Board of Directors Genetic Signatures Limited announced the following planned succession changes to its Board of Directors: the appointment of Ms. Anne Lockwood as a Non-Executive Director on 1 October 2024; the resignation of current Non-Executive Director Dr. Tony Radford; the retirement of Dr. Nick Samaras at the Company's Annual General Meeting on 20 November 2024; and the appointment of Ms. Caroline Waldron as Chair following the Company's 2024 Annual General Meeting on 20 November 2024. Incoming Director, Ms. Lockwood, is currently a Non-Executive Director for the ASX-listed company Mayne Pharma and Chief Financial Officer for Planet Innovation. She brings strong finance and accounting as well as US operations experience gained from senior executive roles in healthcare and life science companies. Ms. Lockwood will join the Board effective 1 October 2024. Dr. Tony Radford has retired from the Board effective immediately in order to reduce his work commitments and focus on personal and family activities. As a recognized leader in the Australian diagnostics space, Dr. Radford has been a highly valued Non-Executive Director of Genetic Signatures since September 2015. After 16 years of dedicated service, Dr. Nick Samaras has advised that he intends to resign from the Board at the Company's upcoming Annual General Meeting. Dr. Samaras has guided the Company through its transformation from a research-based organization to a fully-fledged commercial Company with revolutionary molecular diagnostic products approved in multiple markets around the globe. Current Non-Executive Director Ms. Caroline Waldron will take up the role of Chair following Dr. Samaras' retirement at the Annual General Meeting. The Company is also in the process of recruiting an additional Director to the Board with commercialization experience. New Risk • Jun 13
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (AU$3.1m net loss in 2 years). Announcement • Jun 05
Genetic Signatures Limited Announces That the US Food & Drug Administration Has Cleared the Company's Easyscreen™ Gastrointestinal Parasite Detection Kit and Gs1 Automated Workflow for Marketing and Sale in the US Genetic Signatures Limited announced that the US Food & Drug Administration ("FDA") has cleared the company's EasyScreen™ Gastrointestinal Parasite Detection Kit and GS1 automated workflow for marketing and sale in the US. Genetic Signatures' EasyScreen™ Gastrointestinal Parasite Detection Kit has the broadest coverage of the FDA cleared molecular tests and is able to identify 8 of the most common and clinically relevant gastrointestinal parasites in a single test, representing approximately 90% of all gastrointestinal Parasitic infections in the US. Genetic Signatures'EasyScreen™ Gastrointestinal Parasite Detection Kit is highly automated and is able to provide a result for all 8 targets in approximately 5 hours. The current practice for gastrointestinal parasite testing is predominantly microscopic examination using O&P[3] testing, that is time-consuming, labour intensive, slow to provide a result, of variable sensitivity and frequently has poor patient compliance across multi sample protocols. It is estimated there are approximately 65 million annual cases of parasitic gastrointestinal infections in the US which result in approximately 5.5 million O&P tests each year. Genetic Signatures is well-prepared for the commercial launch of its EasyScreen™ Gastrointestinal Parasite Detection Kit. The Company has installed instruments and completed training at nine customer-experience sites which span a range of customer groups including hospitals, health departments and corporate pathology providers under a customer-experience program. The Company has received positive feedback from these sites and expects some will become the initial commercial customers. Furthermore, the CPT codes which are relevant for providing reimbursement to end users from both public and private payors have been identified. Genetic Signatures expects first commercial sale of the kit in the US within 60 – 90 days of this clearance once appropriately packaged and labelled product is available and the Company's pathology provider customers have completed their internal technology evaluation and approval process. Recent Insider Transactions • Mar 01
Director recently bought AU$59k worth of stock On the 27th of February, Stéphane Chatonsky bought around 113k shares on-market at roughly AU$0.52 per share. This transaction increased Stéphane's direct individual holding by 2x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. New Risk • Feb 22
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: AU$18m Forecast net loss in 2 years: AU$3.1m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$3.1m net loss in 2 years). Shareholders have been diluted in the past year (30% increase in shares outstanding). Market cap is less than US$100m (AU$94.2m market cap, or US$62.0m). Major Estimate Revision • Feb 02
Consensus revenue estimates fall by 28% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from AU$14.1m to AU$10.1m. Forecast losses increased from -AU$0.066 to -AU$0.079 per share. Life Sciences industry in Australia expected to see average net income growth of 20% next year. Consensus price target down from AU$0.80 to AU$0.75. Share price fell 4.0% to AU$0.48 over the past week. Announcement • Jan 25
Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.979326 million. Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.979326 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 21,565,747
Price\Range: AUD 0.37
Transaction Features: Rights Offering Major Estimate Revision • Jan 12
Consensus revenue estimates decrease by 31% The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from AU$20.4m to AU$14.1m. EPS estimate unchanged from -AU$0.066 per share at last update. Life Sciences industry in Australia expected to see average net income growth of 20% next year. Consensus price target down from AU$1.19 to AU$0.80. Share price rose 7.1% to AU$0.45 over the past week. New Risk • Jan 05
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (AU$69.3m market cap, or US$46.5m). Price Target Changed • Nov 22
Price target decreased by 20% to AU$0.90 Down from AU$1.13, the current price target is an average from 2 analysts. New target price is 100% above last closing price of AU$0.45. Stock is down 47% over the past year. The company is forecast to post a net loss per share of AU$0.069 next year compared to a net loss per share of AU$0.098 last year. Buying Opportunity • Nov 16
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 4.9%. The fair value is estimated to be AU$0.61, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 70% in 2 years. Earnings is forecast to grow by 82% in the next 2 years. Announcement • Oct 28
Genetic Signatures Limited, Annual General Meeting, Nov 29, 2023 Genetic Signatures Limited, Annual General Meeting, Nov 29, 2023, at 09:00 AUS Eastern Standard Time. Location: Allens, Deutsche Bank Place, Level 28, 126 Phillip Street, Sydney, NSW 2000 Sydney Nsw 2000 New South Wales Australia Agenda: To consider Re-election of Director Dr Nickolaos Samaras; to consider Re-election of Director Dr Neil Gunn; to consider Adoption of the Remuneration Report; to Approval for the issue of Options to a Director, Caroline Waldron, under the GSS Equity Incentive Plan. Buying Opportunity • Oct 13
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 18%. The fair value is estimated to be AU$0.62, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 70% in 2 years. Earnings is forecast to grow by 82% in the next 2 years. Reported Earnings • Aug 31
Full year 2023 earnings released: AU$0.098 loss per share (vs AU$0.021 profit in FY 2022) Full year 2023 results: AU$0.098 loss per share (down from AU$0.021 profit in FY 2022). Revenue: AU$22.1m (down 38% from FY 2022). Net loss: AU$14.1m (down AU$17.1m from profit in FY 2022). Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 8.6% growth forecast for the Global Life Sciences industry. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance. New Risk • Aug 25
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (AU$6.8m net loss in 2 years). Market cap is less than US$100m (AU$70.3m market cap, or US$45.0m). Major Estimate Revision • Mar 01
Consensus EPS estimates fall by 37% The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -AU$0.06 to -AU$0.082 per share. Revenue forecast of AU$21.7m unchanged since last update. Life Sciences industry in Australia expected to see average net income growth of 8.0% next year. Consensus price target up from AU$0.88 to AU$0.95. Share price rose 5.7% to AU$0.83 over the past week. Price Target Changed • Feb 24
Price target increased by 8.0% to AU$0.95 Up from AU$0.88, the current price target is provided by 1 analyst. New target price is 13% above last closing price of AU$0.84. Stock is down 34% over the past year. The company is forecast to post a net loss per share of AU$0.082 compared to earnings per share of AU$0.021 last year. Reported Earnings • Feb 23
First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.033 profit in 1H 2022) First half 2023 results: AU$0.045 loss per share (down from AU$0.033 profit in 1H 2022). Revenue: AU$10.8m (down 51% from 1H 2022). Net loss: AU$6.48m (down 238% from profit in 1H 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Life Sciences industry in Australia. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Independent Non-Executive Director Tony Radford was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Price Target Changed • Oct 29
Price target decreased to AU$0.90 Down from AU$1.20, the current price target is provided by 1 analyst. New target price is 28% above last closing price of AU$0.70. Stock is down 49% over the past year. The company is forecast to post a net loss per share of AU$0.052 compared to earnings per share of AU$0.021 last year. Announcement • Oct 14
Genetic Signatures Limited, Annual General Meeting, Nov 16, 2022 Genetic Signatures Limited, Annual General Meeting, Nov 16, 2022, at 10:00 AUS Eastern Standard Time. Location: Clifton Venues, Level 13, 60 Margaret St, Sydney New South Wales Australia Agenda: To receive and consider the financial report, the directors' report and the independent auditor's report of the company for the financial year ended 30 June 2022; to consider re-election of Director Dr Anthony Radford; to consider remuneration report; to consider election of a Director Ms Caroline Waldron; to consider Equity Incentive Plan; and to consider other matters. Reported Earnings • Sep 01
Full year 2022 earnings released: EPS: AU$0.021 (vs AU$0.012 in FY 2021) Full year 2022 results: EPS: AU$0.021 (up from AU$0.012 in FY 2021). Revenue: AU$35.6m (up 26% from FY 2021). Net income: AU$3.06m (up 74% from FY 2021). Profit margin: 8.6% (up from 6.2% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is expected to shrink by 36% compared to a 10% growth forecast for the Life Sciences industry in Australia. Over the last 3 years on average, earnings per share has increased by 96% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • Jul 26
Genetic Signatures Limited Announces Clinical Trial Recruitment Completed for US Enteric Kit Genetic Signatures announced it has completed recruitment for the clinical trial of their 3base® EasyScreenTM Enteric Protozoan Diagnostic Kit in the United States (U.S). This is an essential step to support an application to the Food and Drug Administration (FDA), with submission of a 510(k) application planned during the 4th quarter of CY2022. Once cleared, Genetic Signatures will market this unique syndromic PCR test to the U.S. market. Genetic Signatures' EasyScreenTM Enteric Protozoan Diagnostic Kit uses the Company's proprietary 3base® technology to analyse the genetic profiles of protozoan pathogens. This allows, in a single sample, the rapid and accurate detection of up to eight species of clinically relevant gastrointestinal parasites. Results from EasyScreenTM tests are available within hours, compared with days or weeks for culture-based methods, and are typically able to identify more infections than traditional methods. To support Genetic Signatures' 510(k) application, the FDA required the Company to provide data from 1,500 clinical samples collected across three different sites in the U.S. Due to the innovative test design and broad content the samples will be analysed for comparative purposes using commercially available tests where available or with in-house developed validated comparative tests, where no commercially available predicate exists. Once completed, Genetic Signatures anticipates an FDA 510(k) application for its EasyScreenTM Enteric Protozoan Diagnostic Kit to be submitted during the 4th quarter CY2022, after which the FDA will review the application. The FDA has a goal of responding with a decision 90 days from submission. Announcement • May 13
Genetic Signatures Limited Announces Appointment of Caroline Waldron as New Non-Executive Director Genetic Signatures Limited announced that Ms. Caroline Waldron has been appointed as a new Non-Executive Director from 13 May 2022. Ms. Waldron is currently a director of Resimac Group Limited and AMA Group Limited. Her executive experience includes leadership roles in law, HR, marketing, risk and internal audit gained from ASX100 and bluechip organisations. Ms. Waldron's formal training is in law, and she has been admitted to the Bar of England and Wales, and the courts of various jurisdictions including in Australia and New Zealand. Price Target Changed • Apr 27
Price target decreased to AU$1.38 Down from AU$3.20, the current price target is provided by 1 analyst. New target price is 6.2% above last closing price of AU$1.30. Stock is down 3.7% over the past year. The company is forecast to post earnings per share of AU$0.023 for next year compared to AU$0.012 last year. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Non-Independent Non-Executive Director Tony Radford was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 21
First half 2022 earnings: EPS and revenues exceed analyst expectations First half 2022 results: EPS: AU$0.033 (up from AU$0.032 in 1H 2021). Revenue: AU$21.9m (up 16% from 1H 2021). Net income: AU$4.70m (up 4.5% from 1H 2021). Profit margin: 22% (down from 24% in 1H 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Over the next year, revenue is expected to shrink by 9.8% compared to a 17% growth forecast for the industry in Australia. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Announcement • Jan 12
Genetic Signatures Limited Announces 3base® SARS-CoV-2 diagnostic kit registered by TGA for saliva samples Genetic Signatures Limited advises that the Therapeutic Goods Administration (TGA) recently registered a saliva-based protocol for collecting and testing patient samples for SARS-CoV-2 using the Company's 3base® EasyScreenTM SARS-CoV-2 Detection Kit. A recent study from scientists in South Africa demonstrated that saliva swabs could be more effective than mid-turbinate nasal swabs in detecting the Omicron variant in PCR based tests, dueto a higher viral RNA load in saliva than in nasal samples. This is different to other variants such as Delta that are more reliably detected from a nasal swab. The Company announced last month that its current EasyScreenTM SARS-CoV-2 Detection Kit could detect all known variants, including Omicron, again demonstrating the versatility of the 3base® technology. Reported Earnings • Aug 25
Full year 2021 earnings released The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$28.7m (up 107% from FY 2020). Net income: AU$1.76m (up AU$3.84m from FY 2020). Profit margin: 6.1% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Valuation Update With 7 Day Price Move • Aug 23
Investor sentiment improved over the past week After last week's 16% share price gain to AU$1.49, the stock trades at a trailing P/E ratio of 44.6x. Average forward P/E is 47x in the Life Sciences industry globally. Total returns to shareholders of 189% over the past three years. Valuation Update With 7 Day Price Move • Jul 07
Investor sentiment improved over the past week After last week's 27% share price gain to AU$1.40, the stock trades at a trailing P/E ratio of 41.9x. Average forward P/E is 46x in the Life Sciences industry globally. Total returns to shareholders of 278% over the past three years. Price Target Changed • Jul 02
Price target decreased to AU$2.20 Down from AU$3.20, the current price target is provided by 1 analyst. New target price is 98% above last closing price of AU$1.11. Stock is down 56% over the past year. Major Estimate Revision • Jun 29
Consensus revenue estimates fall to AU$28.0m The consensus outlook for revenues in 2021 has deteriorated. 2021 revenue forecast decreased from AU$33.5m to AU$28.0m. EPS estimate fell from AU$0.037 to AU$0.01 per share. Net income forecast to shrink 137% next year vs 24% growth forecast for Life Sciences industry in Australia . Consensus price target reaffirmed at AU$3.20. Share price fell 7.6% to AU$1.10 over the past week. Is New 90 Day High Low • Mar 05
New 90-day low: AU$1.58 The company is down 12% from its price of AU$1.78 on 04 December 2020. The Australian market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 9.0% over the same period. Reported Earnings • Feb 23
First half 2021 earnings released: EPS AU$0.032 (vs AU$0.021 loss in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$18.9m (up 411% from 1H 2020). Net income: AU$4.50m (up AU$6.84m from 1H 2020). Profit margin: 24% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has increased by 81% per year, which means it is tracking significantly ahead of earnings growth. Analyst Estimate Surprise Post Earnings • Feb 23
Revenue beats expectations, earnings disappoint Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) missed analyst estimates by 3.5%. Over the next year, revenue is forecast to grow 1.5%, compared to a 42% growth forecast for the Life Sciences industry in Australia. Is New 90 Day High Low • Dec 17
New 90-day low: AU$1.65 The company is down 18% from its price of AU$2.00 on 18 September 2020. The Australian market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 1.0% over the same period. 